ストックスクリーナーアプリを入手
47.30
0.19%
-0.09
アフターアワーズ：
47.30
Vaxcyte Inc (PCVX) 最新ニュース
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
Jones Hill Capital LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
(PCVX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
DIADEMA PARTNERS LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
TradingKey - TradingKey
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 105% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Nan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - Moomoo
PCVX Technical Analysis | Trend, Signals & Chart Patterns | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Vaxcyte Slides After Q1 Loss Widens as Spending Ramps Ahead of Key Phase 3 Readouts - Moomoo
Vaxcyte slides after Q1 loss widens as spending ramps ahead of key Phase 3 readouts - Quiver Quantitative
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating - Moomoo
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Higher Vaxcyte (NASDAQ: PCVX) Q1 loss as late-stage trials expand - Stock Titan
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxcyte | 8-K: Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Vaxcyte (NASDAQ: PCVX) advances Phase 3 VAX-31 program and holds $2.7B cash - Stock Titan
FMR LLC discloses 11.4% stake in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Vaxcyte | 10-Q: Q1 2026 Earnings Report - Moomoo
Vaxcyte (NASDAQ:PCVX) Stock Price Down 6.8%What's Next? - MarketBeat
Vaxcyte, Inc. (PCVX) Investor Outlook: Analyzing a 91% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Jennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market - Seeking Alpha
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares By Investing.com - Investing.com Canada
Vaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in Stock - MarketBeat
Vaxcyte COO Jim Wassil sells $127,869 in PCVX shares - Investing.com
Vaxcyte (PCVX) COO Jim Wassil sells 2,250 shares in Rule 10b5-1 trade - Stock Titan
PCVX (PCVX) insider James Wassil files planned sales totaling $566,913.91 - Stock Titan
Vaxcyte Executive Compensation, Directors, and Corporate Governance Overview 2025 - Minichart
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard (PCVX) holds 7.25M Vaxcyte shares, reports 5.03% stake - Stock Titan
Pictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring the 83% Potential Upside in Vaccine Innovation - DirectorsTalk Interviews
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte Completes Enrollment for Phase 3 VAX-31 Vaccine Trials - HarianBasis.co
[ARS] Vaxcyte, Inc. SEC Filing - Stock Titan
Vaxcyte (NASDAQ: PCVX) 2026 proxy on directors, auditor and say-on-pay - Stock Titan
Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage - Insider Monkey
5 Best 52-Week High US Stocks to Buy - Insider Monkey
Trading Systems Reacting to (PCVX) Volatility - Stock Traders Daily
InvestingPro Fair Value predicted Vaxcyte’s 36% decline By Investing.com - Investing.com South Africa
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):